Switching from adalimumab originator to biosimilar: a 3-year retrospective cohort analysis

Our three year retrospective cohort study demonstrated that the vast majority of patients tolerated the switch from adalimumab originator to adalimumab biosimilar, with a 19% switchback rate. All patients who switched back to originator from biosimilar recovered from loss of efficiency and reported adverse events. Physicians therefore should be confident in switching patients with well controlled psoriasis to adalimumab biosimilars.